Don Healey - 24 Jan 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Jan 2024, 19:09:25 UTC
Prior SEC filing
03 Oct 2023
Next SEC filing
07 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nick Harvey, Attorney-in-Fact

Key filing fact

Don Healey filed Form 4 for Adicet Bio, Inc. (ACET) on 26 Jan 2024.

Key facts

  • This page summarizes Don Healey's Form 4 filing for Adicet Bio, Inc. (ACET).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 26 Jan 2024, 19:09.

Change

  • Previous filing in this sequence was filed on 03 Oct 2023.
  • Current net transaction value: -$11,688.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACET transaction

Common Stock

Tax liability

Transaction value
$11,688
Shares
-4,870
Change %
-8.5%
Price
$2.40
Shares after
52,629
Date
24 Jan 2024
Ownership
Direct
Footnotes
F1
ACET transaction

Common Stock

Award

Transaction value
$0
Shares
+19,700
Change %
+37%
Price
$0.000000
Shares after
72,329
Date
24 Jan 2024
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACET transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+211,633
Change %
Price
$0.000000
Shares after
211,633
Date
24 Jan 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
211,633
Exercise price
$2.40
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

Footnote F2

The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Footnote F3

1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .